Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2026-02-04 22:40Core Viewpoint - The company has entered into guarantee agreements to support its subsidiaries' financing needs, ensuring operational continuity and financial stability [3][5][13]. Group 1: Guarantee Agreements - In January 2026, the company’s subsidiary, Lijuz Pharmaceutical Group, signed guarantee agreements with three banks, with total guarantee amounts of RMB 10,000 million, RMB 30,000 million, and RMB 60,000 million [3]. - The guarantees are for Lijuz Pharmaceutical's wholly-owned or controlled subsidiaries, and there are no related party guarantees involved [3]. - The company has authorized its legal representative to sign relevant documents regarding the guarantees, assuming joint liability [4][5]. Group 2: Financing Support Framework - A framework agreement was established for Lijuz Group to provide continuous financing guarantees for its subsidiary, Lijuz Monoclonal Antibody, from January 1, 2025, to December 31, 2027, with an annual limit of RMB 21,000 million [5]. - The company will provide counter-guarantees based on its equity stake in Lijuz Monoclonal Antibody, ensuring financial backing until the end of Lijuz Group's guarantee obligations [5][15]. Group 3: Financial Health and Risk Management - As of January 31, 2026, the total guarantee balance of the company is RMB 228,478.14 million, which is 15.72% of the latest audited net assets [16]. - There are no overdue guarantees as of the same date, indicating effective risk management and financial health [17].